Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.54 | N/A | +69.60% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.54 | N/A | +69.60% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the strong EPS results, highlighting their commitment to pipeline advancements. They emphasized ongoing efforts to create shareholder value.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline and delivering value.
Neurocrine Biosciences reported a strong EPS performance, significantly exceeding expectations. The stock reacted positively, rising 3.56% in response to the earnings surprise. Investors may view the strong EPS as a sign of the company's financial health, although no revenue figures or future guidance were disclosed.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
REVVITY INC